Previous 10 | Next 10 |
Gainers: HCW Biologics (NASDAQ:HCWB) +132%. InflaRx (NASDAQ:IFRX) +45%. Digital Brands Group (NASDAQ:DBGI) +43%. Lucid Group (NASDAQ:LCID) +38%. Wolfspeed (NASDAQ:WOLF) +32%. LendingClub Corporation (NYSE:LC) +32%. Overstock (NASDAQ:OSTK) +25%. Impinj (NASDAQ:PI) +24%. Triterras (NASDAQ:TRIT)...
Shares of Alnylam Pharmaceuticals (NASDAQ: ALNY) were tanking on Thursday after the company reported its earnings results for the third quarter. The biopharmaceutical company's stock is down 14.1% as of 1:34 p.m. EDT, likely due to the company missing revenue estimates for the q...
Gainers: HCW Biologics HCWB +115%, InflaRx IFRX +40%, Inspira Technologies Oxy (NASDAQ:IINN) +37%, Community Health Systems (NYSE:CYH) +16%, Invacare (NYSE:IVC) +11%. Losers: Rafael RFL -80%, DBV Technologies (NASDAQ:DBVT) -13%, Alny...
Shares of Alnylam Pharmaceuticals (ALNY -17.9%) are down in morning trading after the RNAi biotech missed Q3 earnings estimates on both EPS and revenue. Alnylam's YoY net loss narrowed 19% to $204.5M. Net loss per common share went to $1.72 from $2.18. Although revenue grew 49% YoY to $187.6M...
Alnylam Pharmaceuticals (NASDAQ:ALNY) has announced planned CEO leadership transition. Founding Alnylam CEO John Maraganore will hand over the role to Yvonne Greenstreet at year-end 2021. Greenstreet currently serves as the company's President and COO. Maraganore joined Alnylam in 2002 as the...
Alnylam Pharmaceuticals (NASDAQ:ALNY): Q3 Non-GAAP EPS of -$1.51 misses by $0.27; GAAP EPS of -$1.72 misses by $0.15. Revenue of $187.63M (+49.1% Y/Y) misses by $31.06M. Press Release Reiterated 2021 Financial Guidance, Including Combined Net Product Revenues of $640-$665 Million For furthe...
− Achieved Third Quarter 2021 Combined Net Product Revenues of $167 Million for ONPATTRO ® , GIVLAARI ® , and OXLUMO ® – − Reported Positive Topline 18-Month Results from HELIOS-A Phase 3 Study of Vutrisiran in hATTR Amyloidosis ...
− Founding Alnylam CEO John Maraganore to Transition CEO Leadership to Alnylam President Yvonne Greenstreet at Year End – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the planned CEO transition...
– Vutrisiran Met All 18-Month Secondary Endpoints, Including Statistically Significant Improvements in Progression of Neuropathy, Quality of Life (QOL), Gait Speed, Nutritional Status and Overall Disability, Relative to External Placebo – – At Month 18, Vu...
Alnylam Receives Positive Reimbursement Recommendation from the Canadian Agencies for Drugs and Technology in Health (CADTH) for use of GIVLAARI® for the Treatment of Acute Hepatic Porphyria (AHP) in Adults Canada NewsWire -- GIVLAARI reduces Chronic Pain, Improve...
News, Short Squeeze, Breakout and More Instantly...
Alnylam Pharmaceuticals Inc. Company Name:
ALNY Stock Symbol:
NASDAQ Market:
Alnylam Pharmaceuticals Inc. Website:
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2024 on Thursday, August 1, 2024, before the U.S. financial markets open. Management will provide an update on th...
2024-06-29 16:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...